Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Rivaroxaban

rivaroxaban

Primary Outcomes

Measure

Time to "First Major" Bleeding event

time frame:
Up to 25 months

Secondary Outcomes

Measure

Time to "First Any" Bleeding event

time frame:
Up to 25 months

Major Bleeding-Related Healthcare Utilization

time frame:
Up to 25 months

Any Bleeding-Related Healthcare Utilization

time frame:
Up to 25 months

Major Bleeding-Related direct medical cost

time frame:
Up to 25 months

Any Bleeding-Related direct medical cost

time frame:
Up to 25 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria:
- Patients ≥18 years old as of the index date
- At least 1 diagnosis of atrial fibrillation in the 12 months prior to or on index
date, identified by any medical claim
- At least one year of baseline period and continuous enrollment for at least 12 months
prior to index date Individuals with NVAF who were using oral anticoagulants (i.e.,
warfarin, dabigatran, rivaroxaban and apixaban) within the study period beginning Jan
1, 2012 through December 31, 2013 or last date of the last data cut available at the
time of execution of the study
Exclusion Criteria:
- Patients with evidence of valvular heart disease, thyrotoxicosis, pericarditis,
mitral stenosis, Venous thromboembolism(VTE), heart surgery, and endocarditis during
the baseline period any time prior to or on index date
- Patients with any evidence of pregnancy at any time during the baseline will be
excluded

Rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots.